Research on Timing of Liraglutide Therapy in Patients With Obesity After Metabolic Surgery

What Was Tested

The trial (phase 4) is built around Liraglutide for fat loss, obesity & body recomposition.

It had four arms (groups): control group (sham comparator), Liraglutide 6 month group (experimental), Liraglutide 9 month group (experimental) and Liraglutide 12 month group (experimental).

Receive guidance on diet and exercise throughout the program, without the use of drugs.

The registry classes the interventions as behavioral and drug.

Who Took Part

Enrollment: 100 actual participants took part.

It was open to people of any sex aged from 18 years up to 65 years.

Healthy volunteers were not accepted; participants needed the condition being studied.

Examples of who could join: Patients 6 months after metabolic surgery;. 18 years ≤ age ≤ 65 years;. Body Mass Index (BMI) ≥ 28 kg/m\^2.

The full record lists 3 inclusion and 5 exclusion criteria; among the exclusions: history of medullary thyroid carcinoma, men-2 or other malignancies; pancreatitis or severe gastrointestinal disease, pregnancy or lactation; use of anti-obesity drugs or other interventional trials within 3 months or major uncontrolled illness.

How the Study Was Run

It was run as a non-randomized, parallel-group and open-label study.

Groups ran in parallel: each of the fat loss, obesity & body recomposition participants stayed in one arm throughout.

Being open-label, the Liraglutide study did not mask who received what.

It started in 2023-09-01 with completion listed for 2025-06-01.

It ran at 1 site in China.

Its stated primary purpose is treatment.

What Was Measured

The main thing measured (primary outcome): Change in %TWL from baseline to endpoint across patient groups (time frame: 48 weeks from enrollment).

It also tracked 5 secondary outcomes, for example Change in BMI from baseline to endpoint across patient groups, Change in body composition from baseline to endpoint across patient groups, Changes in blood pressure from baseline to endpoint, Changes in fasting blood glucose from baseline to endpoint and Change in HbA1c from baseline to endpoint across patient groups.

What This Means in Plain Language

Put simply, this is a phase 4, non-randomized trial of Liraglutide in 100 people with fat loss, obesity & body recomposition.

The trial is marked completed; no results are posted to the registry yet, so nothing here describes outcomes.

More context: the Liraglutide compound page, Fat loss, obesity & body recomposition research.